TNFRSF8 and anaplastic large cell lymphoma: Specifically, of the two patients with ALCL, one patient with ALKpos ALCL had a dramatic response after the first anti-CD30 CAR-T cell infusion, and after the fourth infusion, achieved a CR that was maintained for nine months.